Top News
Nelfinavir Plus Lenalidomide, Dexamethasone Improves Response in Lenalidomide-Refractory Multiple Myeloma
Real-World Insight on Patients With Multiple Myeloma: Results Drawn From a Large Health Plan
Intrauterine Device Use May Reduce Incidence of Ovarian Cancer
A Decade of Treatments Administered to Elderly Patients With Hodgkin Lymphoma at a Single Center: New Insights
Malnutrition Common in Older Brazilians Hospitalized for Cancer
Use of Interim PET/CT to Stratify Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma
Venetoclax Plus Hypomethylating Agents May Offer Treatment Backbone for High-Risk AML
Incidence of GI Adverse Events Associated With CAR-T Therapy for Lymphoma or Leukemia Is Low
Pembrolizumab Shows Overall Survival Benefit at 3 Years in Advanced NSCLC
EDITORIAL ADVISORY BOARD
E. David Crawford, MD
Jeffrey M. Farma, MD
Featured
-
Ribociclib Shown to Penetrate the Blood-Brain Barrier in Glioblastoma
A phase 0 study of ribociclib in patients with recurrent glioblastoma seeks to inform the feasibility of the use of CDK 4/6 inhibitors for deadly brain tumors. -
Phase 3 Trial for Oncolytic Viral Therapy Pexa-Vec in Advanced Liver Cancer Terminated Early
Pexa-Vec, in combination with sorafenib, has failed an interim futility analysis, leading to the early termination of the trial. -
IASLC 2019 Coverage
News coverage from the IASLC 2019 World Conference in Barcelona, Spain. -
Microbiome Analysis May Be a Feasible Diagnostic Test for Prostate Cancer
The microbiome could have a role in the diagnosis of PrCa. -
Radio-Enhancing Nanoparticles in Sarcoma: Readout of Clinical Outcomes Expected by 2020
Radiation-enhancing particles appear to be a promising tool for improving results with radiotherapy — perhaps even across various cancers. -
Recent Advances Offer Paths Forward for Developing Predictive Biomarkers in Cancer Immunotherapy
Recent advances in predictive biomarker development clarify how best to determine PD-L1 expression in tumor cells. -
Knowing the Appropriateness of Running Noninferiority Trials in Oncology
Researches took a critical look at noninferiority trials and determined that when a new intervention is “not worse,” the possibility exists that it is not better, either. -
Experiments in Mice Suggest Fecal Transplantation May Influence Pancreatic Tumor Growth
Researchers showed that survival in pancreatic cancer may be influenced by the tumor microbiome and that tumor growth can be influenced via fecal transplantation. -
Ibrutinib Shown to Cross the Blood-Brain Barrier in CNS Lymphoma
The authors proved that the drug was able to cross the blood-brain barrier in a concentration that was effective.
More Features
The Case for Immunotherapy Trials That Reflect the Real World of Metastatic Melanoma
The problem of low representation of racial minorities is especially urgent during the era of immunotherapy trials.
Treatment Delays With CAR-T Therapy: A High Price to Pay
A treatment delay of 6 months was found to result in up to a 67.3% loss in social value for patients receiving chimeric antigen receptor T-cell therapy.
Comparison Study Shows Predictive Value for CSCC of the Head and Neck of BWH vs AJCC 8
A team of researchers sought to determine if BWH Tumor Classification System classified tumors more accurately than AJCC 8, and their sensitivity and specificity for predicting poor outcomes.
Pharmacovigilance Needed for Immune Checkpoint Inhibitor Therapy in NSCLC
Immune checkpoint inhibitor therapies have improved survival in patients with non-small cell lung cancer, but they have also been linked to immune-related adverse events affecting various organs, including the lungs.
New DARZALEX® (Daratumumab) Combination Expands Options for Use in Newly Diagnosed, Transplant Ineligible Multiple Myeloma Patients
Combination therapy has become a common way to treat many cancers, as the complexity presented by certain types requires a variety of therapies to attack it.
